Recently, an old patient had liver cancer for 2 years after liver transplantation and had been taking doxorubicin for 2 years. However, this means that Doxorubicin is still unable to effectively control the recurrence or metastasis of tumor. It is not uncommon to see such patients in clinical practice, how to adjust the treatment plan after surgery? According to foreign reports, in advanced hepatocellular carcinoma treated with sorafenib + siroda + lexadine, i.e. SECOX regimen, the progression-free survival is more than double than that of sorafenib alone. However, the combination of these three drugs can have certain effects on the patient’s liver and kidney function and hematopoietic system, which depends on the situation of different patients.